Substance / Medication

Linzagolix

Overview

Active Ingredient
linzagolix
RxNorm CUI
2621019

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials.
Becker Sven, Dolmans Marie-Madeleine, Herrera Francisco Carmona et al. · BJOG · 2025
PMID: 40326221RCTFull text (PMC)
Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials.
Donnez Jacques, Becker Christian M, Mangler Mandy et al. · Fertil Steril · 2025
PMID: 39755138RCT
Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis.
Donnez Olivier, Donnez Jacques · Fertil Steril · 2020
PMID: 32507315Case Report
Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review.
Donnez Jacques, Cacciottola Luciana, Squifflet Jean-Luc et al. · Drug Des Devel Ther · 2023
PMID: 36789095ReviewFull text (PMC)
Sequential and Personalized Linzagolix Therapy for Uterine Fibroids: A Rational Clinical Approach.
Perelló-Capó Josep, Cristóbal-García Ignacio, Calaf-Alsina Joaquim · Womens Health Rep (New Rochelle) · 2025
PMID: 41133175OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Linzagolix (substance)
SNOMED CT
1351549009
UMLS CUI
C5235403
RxNorm CUI
2621019

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.